NCT05921890View on ClinicalTrials.gov

To Evaluate the Safety and Tolerability of Multiple Doses of GS3-007a Oral Solution in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 19, 2023

Primary Completion Date

October 28, 2023

Study Completion Date

October 28, 2023

Conditions
Healthy Subject
Interventions
DRUG

GS3-007 oral liquid

The dosage was calculated according to body weight, once a day or twice a day.

Trial Locations (1)

610000

Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu

All Listed Sponsors
lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY